The activated endocannabinoid system in atherosclerosis: Driving force or protective mechanism?

Current Drug Targets

Volumn 16, Issue 4, 2015, Pages 334-341

  Steffens, Sabine ^a   Pacher, P ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Cannabinoid receptor CB1; CB2; Diacylglycerol lipase; Eicosanoid; Fatty acid amide hydrolase; Monoacylglycerol lipase

Indexed keywords

ANANDAMIDE; ANGIOTENSIN II; ANTINEOPLASTIC ALKALOID; APOLIPOPROTEIN E; BAY 38 7271; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CD36 ANTIGEN; CXCL1 CHEMOKINE; CYCLOOXYGENASE 2 INHIBITOR; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; GAMMA INTERFERON; GELATINASE B; KN 38 7271; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RIMONABANT; SPHINGOSINE 1 PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CLINICAL ASSESSMENT; DISEASE COURSE; DRUG TARGETING; DYSLIPIDEMIA; HEART FUNCTION; HEMODYNAMICS; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; VASODILATATION; AGONISTS; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR SYSTEM; DRUG EFFECTS; HEART CONTRACTION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PROTECTION; RISK FACTOR;

ATHEROSCLEROSIS; BLOOD PRESSURE; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CARDIOVASCULAR SYSTEM; CHOLESTEROL; ENDOCANNABINOIDS; HUMANS; MOLECULAR TARGETED THERAPY; MYOCARDIAL CONTRACTION; PROTECTIVE FACTORS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84928897682     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141202113225     Document Type: Article

References (117)

1. [I] Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
2. [2] Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
3. [3] Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
4. [4] Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
5. [5] Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
6. [6] De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004; 141: 765-74.
7. [7] Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007; 114: 13-33.
8. [8] Balenga NA, Aflaki E, Kargl J, et al. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res 2011; 21: 1452-69.
9. [9] Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-101.
10. [10] Bonz A, Laser M, Kullmer S, et al. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 2003; 41: 657-64.
11. [11] Batkai S, Pacher P, OseiHyiaman D,et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004; 110: 1996-2002.
12. [12] Mukhopadhyay P, Batkai S, Rajesh M, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 2007; 50: 528-36.
13. [13] Rajesh M, Mukhopadhyay P, Batkai S, et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007; 293: H2210-8.
14. [14] Rajesh M, Mukhopadhyay P, Hasko G, Huffman JW, Mackie K and Pacher P CB(2) cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 2008; 153: 347-57.
15. [15] Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-31.
16. [16] Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-43.
17. [17] Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-305.
18. [18] Mallat A, Lotersztajn S. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol 2008; 294: G9-G12.
19. [19] Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54-61.
20. [20] Noe SN, Newton C, Widen R, Friedman H, Klein TW. Modulation of CB1 mRNA upon activation of murine splenocytes. Adv Exp Med Biol 2001; 493: 215-21.
21. [21] Samson MT, Small-Howard A, Shimoda LM, Koblan-Huberson M, Stokes AJ, Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 2003; 170: 4953-62.
22. [22] Matias I, Pochard P, Orlando P, Salzet M, Pestel J, Di Marzo V. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 2002; 269: 3771-8.
23. [23] Nong L, Newton C, Friedman H, Klein TW. CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types. Adv Exp Med Biol 2001; 493: 229-33.
24. [24] Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310: 329-32.
25. [25] Pacher P, Gao B. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. Am J Physiol Gastrointest Liver Physiol 2008; 294: G850-4.
26. [26] Jiang LS, Pu J, Han ZH, Hu LH, He B. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc Res 2009; 81: 805-13.
27. [27] Rajesh M, Mukhopadhyay P, Hasko G, Pacher P. Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem Biophys Res Commun 2008; 377: 1248-52.
28. [28] Demuth DG, Molleman A. Cannabinoid signalling. Life Sci 2006; 78: 549-63.
29. [29] Leterrier C, Bonnard D, Carrel D, Rossier J, Lenkei Z. Constitutive endocytic cycle of the CB1 cannabinoid receptor. The Journal of biological chemistry 2004; 279: 36013-21.
30. [30] Daigle TL, Kwok ML, Mackie K. Regulation of CB1 cannabinoid receptor internalization by a promiscuous phosphorylation-dependent mechanism. J Neurochem 2008; 106: 70-82.
31. [31] Ritter SL, Hall RA. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol 2009; 10: 819-30.
32. [32] Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annual review of pharmacology and toxicology 2012; 52: 179-97.
33. [33] Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005: 1-51.
34. [34] Montecucco F, Matias I, Lenglet S, et al. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 2009; 205: 433-41.
35. [35] Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007; 18: 129-40.
36. [36] Park YM CD36, a scavenger receptor implicated in atherosclerosis. Exp Mol Med 2014; 46: e99.
37. [37] Miller AM, Stella N CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 2008; 153: 299-308.
38. [38] Maestroni GJ The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. Faseb J 2004; 18: 1914-6.
39. [39] Walter L, Franklin A, Witting A, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 2003; 23: 1398-405.
40. [40] Pacher P, Batkai S, Kunos G. Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology 2005; 48: 1130-8.
41. [41] Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 1996; 118: 2023-8.
42. [42] Lake KD, Martin BR, Kunos G, Varga K. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 1997; 29: 1204-10.
43. [43] Gardiner SM, March JE, Kemp PA and Bennett T Complex regional haemodynamic effects of anandamide in conscious rats. Br J Pharmacol 2002; 135: 1889-96.
44. [44] Wheal AJ, Bennett T, Randall MD, Gardiner SM. Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. Br J Pharmacol 2007; 152: 717-24.
45. [45] Pacher P, Batkai S, Osei-Hyiaman D, et al. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 2005; 289: H533-41.
46. [46] Wagner JA, Jarai Z, Batkai S, Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 2001; 423: 203-10.
47. [47] Pacher P, Batkai S and Kunos G The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
48. [48] Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Batkai S, Kunos G Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension 2008; 52: 601-7.
49. [49] Szekeres M, Nadasy GL, Turu G, et al. Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors. J Biol Chem 2012; 287: 31540-50.
50. [50] Randall MD, Harris D, Kendall DA, Ralevic V. Cardiovascular effects of cannabinoids. Pharmacol Ther 2002; 95: 191-202.
51. [51] Mendizabal VE, Adler-Graschinsky E. Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol 2007; 151: 427-40.
52. [52] Quercioli A, Pataky Z, Vincenti G, et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 2011; 32: 1369-78.
53. [53] Quercioli A, Pataky Z, Montecucco F, et al. Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. JACC Cardiovasc Imaging 2012; 5: 805-15.
54. [54] Quercioli A, Montecucco F, Pataky Z, et al. Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. Eur Heart J 2013; 34: 2063-73.
55. [55] Lobato NS, Filgueira FP, Prakash R, et al. Reduced endothelium-dependent relaxation to anandamide in mesenteric arteries from young obese Zucker rats. PLoS One 2013; 8: e63449.
56. [56] Maslov LN, Lasukova OV, Krylatov AV, Uzhachenko RV, Pertwee R. Selective cannabinoid receptor agonist HU-210 decreases pump function of isolated perfused heart: role of cAMP and cGMP. Bull Exp Biol Med 2004; 138: 550-3.
57. [57] Krylatov AV, Maslov LN, Lasukova OV, Pertwee RG. Cannabinoid receptor antagonists SR141716 and SR144528 exhibit properties of partial agonists in experiments on isolated perfused rat heart. Bull Exp Biol Med 2005; 139: 558-61.
58. [58] Pacher P, Batkai S, Kunos G. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 2005: 599-625.
59. [59] Sterin-Borda L, Del Zar CF, Borda E. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Biochem Pharmacol 2005; 69: 1705-13.
60. [60] Wang PF, Jiang LS, Bu J, et al. Cannabinoid-2 receptor activation protects against infarct and ischemia-reperfusion heart injury. J Cardiovasc Pharmacol 2012; 59: 301-7.
61. [61] Weis F, Beiras-Fernandez A, Sodian R, et al. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. J Mol Cell Cardiol 2010; 48: 1187-93.
62. [62] Lenglet S, Thomas A, Soehnlein O, et al. Fatty acid amide hydrolase deficiency enhances intraplaque neutrophil recruitment in atherosclerotic mice. Arterioscler Thromb Vasc Biol 2013; 33: 215-23.
63. [63] Sugamura K, Sugiyama S, Nozaki T, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009; 119: 28-36.
64. [64] Klein TW Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400-11.
65. [65] Lichtman AH, Shelton CC, Advani T, Cravatt BF. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 2004; 109: 319-27.
66. [66] Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004; 113: 1202-9.
67. [67] Long JZ, LaCava M, Jin X, Cravatt BF. An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase. J Lipid Res 2011; 52: 337-44.
68. [68] Hoyer FF, Khoury M, Slomka H, et al. Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice. J Mol Cell Cardiol 2014; 66: 126-32.
69. [69] Molica F, Burger F, Thomas A, et al. Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation. J Lipid Res 2013; 54: 1360-8.
70. [70] Dol-Gleizes F, Paumelle R, Visentin V, et al. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2009; 29: 12-8.
71. [71] Tiyerili V, Zimmer S, Jung S, et al. CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res Cardiol 2010; 105: 465-77.
72. [72] Molica F, Morel s, Kwak BR, Rohner-Jeanrenaud F, Steffens S. Adipokines at the crossroad between obesity and cardiovascular disease. Thromb Haemost 2014.
73. [73] Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-34.
74. [74] Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008; 299: 1547-60.
75. [75] Ruby MA, Nomura DK, Hudak CS, et al. Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. Proc Natl Acad Sci U S A 2008; 105: 14561-6.
76. [76] Rosenson RS, Brewer HB, Jr., Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012; 125: 1905-19.
77. [77] Lewis GF and Rader DJ New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-32.
78. [78] Kruth HS Receptor-independent fluid-phase pinocytosis mechanisms for induction of foam cell formation with native low-density lipoprotein particles. Curr Opin Lipidol 2011; 22: 386-93.
79. 79[] Pacher P, and Mechoulam R, Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011; 50: 193-211.
80. [80] Montecucco F, Di Marzo V, da Silva RF, et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease- mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012; 33: 846-56.
81. [81] Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434: 782-6.
82. [82] Molica F, Matter CM, Burger F, et al. The cannabinoid receptor CB2 protects against balloon-induced neointima formation. Am J Physiol Heart Circ Physiol 2012.
83. [83] Montecucco F, Lenglet S, Braunersreuther V, et al. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol 2009; 46: 612-20.
84. [84] Molica F, Matter CM, Burger F, et al. Cannabinoid receptor CB2 protects against balloon-induced neointima formation. Am J Physiol Heart Circ Physiol 2012; 302: H1064-74.
85. 85[] Steffens S, and Pacher P, Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies. Br J Pharmacol 2012; 167: 313-23.
86. [86] Delsing DJ, Leijten FP, Arts K, et al. Cannabinoid Receptor 2 Deficiency in Haematopoietic cells Aggravates Early Atherosclerosis in LDL Receptor Deficient Mice. Open Cardiovasc Med J 2011; 5: 15-21.
87. [87] Hoyer FF, Steinmetz M, Zimmer S, et al. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J Mol Cell Cardiol 2011; 51: 1007-14.
88. [88] Netherland CD, Pickle TG, Bales A and Thewke DP Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis 2010; 213: 102-8.
89. [89] Willecke F, Zeschky K, Ortiz Rodriguez A, et al. Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice. PLoS One 2011; 6: e19405.
90. 90[] DiMarzo V Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? Nat Clin Pract Cardiovasc Med 2008; 5: 610-2.
91. [91] Silvestri C, Di Marzo V. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin Investig Drugs 2012; 21: 1309-22.
92. [92] Klumpers LE, Fridberg M, de Kam ML, et al. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol 2013; 76: 846-57.
93. [93] Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010; 120: 2953-66.
94. [94] Jourdan T, Godlewski G, Cinar R, et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med 2013; 19: 1132-40.
95. [95] Tam J, Cinar R, Liu J, et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab 2012; 16: 167-79.
96. [96] Mauler F, Horvath E, De Vry J, et al. BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev 2003; 9: 343-58.
97. [97] Firsching R, Piek J, Skalej M, Rohde V, Schmidt U, Striggow F. Early survival of comatose patients after severe traumatic brain injury with the dual cannabinoid CB1/CB2 receptor agonist KN38-7271: a randomized, double-blind, placebo-controlled phase II trial. J Neurol Surg A Cent Eur Neurosurg 2012; 73: 204-16.
98. [98] Schmidt W, Schafer F, Striggow V, Frohlich K and Striggow F Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia. Neuroscience 2012; 227: 313-26.
99. [99] Blankman JL and Cravatt BF Chemical probes of endocannabinoid metabolism. Pharmacol Rev 2013; 65: 849-71.
100. [100] Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81.
101. [101] Godlewski G, Alapafuja SO, Batkai S, et al. Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem Biol 2010; 17: 1256-66.
102. [102] Karsak M, Gaffal E, Date R, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007; 316: 1494-7.
103. [103] Mukhopadhyay P, Horvath B, Rajesh M, et al. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med 2011; 50: 179-95.
104. [104] Chanda PK, Gao Y, Mark L, et al. Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol 2010; 78: 996-1003.
105. [105] Schlosburg JE, Blankman JL, Long JZ, et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 2010; 13: 1113-9.
106. [106] Long JZ, Li W, Booker L, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009; 5: 37-44.
107. [107] Long JZ, Nomura DK and Cravatt BF Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 2009; 16: 744-53.
108. [108] Ghosh S, Wise LE, Chen Y, et al. The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci 2013; 92: 498-505.
109. [109] Cao Z, Mulvihill MM, Mukhopadhyay P, et al. Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology 2013; 144: 808-817 e15.
110. [110] Nomura DK, Morrison BE, Blankman JL, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011; 334: 809-13.
111. [111] Costola-de-Souza C, Ribeiro A, Ferraz-de-Paula V, et al. Monoacylglycerol lipase (MAGL) inhibition attenuates acute lung injury in mice. PLoS One 2013; 8: e77706.
112. 112[] Rouzer CA and Marnett LJ Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev 2011; 111: 5899-921.
113. [113] Hsu KL, Tsuboi K, Adibekian A, Pugh H, Masuda K, Cravatt BF. DAGLbeta inhibition perturbs a lipid network involved in macrophage inflammatory responses. Nat Chem Biol 2012; 8: 999-1007.
114. [114] Bisogno T, Mahadevan A, Coccurello R, et al. A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects. Br J Pharmacol 2013; 169: 784-93.
115. [115] Bisogno T, Cascio MG, Saha B, et al. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 2006; 1761: 205-12.
116. [116] Hoover HS, Blankman JL, Niessen S, Cravatt BF. Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. Bioorg Med Chem Lett 2008; 18: 5838-41.
117. [117] Gao Y, Vasilyev DV, Goncalves MB, et al. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci 2010; 30: 2017-24.